Cardio Diagnostics Holdings, Inc. (CDIO) stock

CDIONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31Also trades as CDIOW

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 4/30

$1.89+0.02 (+1.07%)

Close on Nov 13, 2026Market cap $5.59MP/E –Yield –

Cardio Diagnostics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Cardio Diagnostics's price to sales ratio was 383.3× on Nov 11, 2026, against 352.9× a year earlier. Over the last 2 years it ranged from 132.8× to 437.2×, with a median of 326.8×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	383.3×	+142.7
2025	Dec 31, 2025	240.6×	−17.8
2024	Nov 29, 2024	258.4×	–

Where these numbers come from

Parsed from the XBRL in Cardio Diagnostics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-30 reverse split on May 13, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CDIO.

Compare: CDIO vs VRAX · CDIO vs AWHL · CDIO vs PRFX · CDIO vs BDPT · CDIO vs SNTI

Operating margin-42649.8% · median -3808.2%

Net margin-42721.9% · median -5219.2%

Company	Revenue	Growth
AWHL	$170.00K	–
BDPT	$25.56K	+694.1%
CDIO	$15.19K	–
VRAX	–	–
PRFX	–	–
SNTI	–	–

Company

Exchange: Nasdaq
Industry: In Vitro & In Vivo Diagnostic Substances
Fiscal year ends: December 31
Employees: 7
Auditor: Prager Metis CPAs, LLC
SEC CIK: 1870144

Advertisement
300 × 250

See a number that looks wrong?

Cardio Diagnostics price to sales ratio

Price to Sales Ratio at the end of each year

More Cardio Diagnostics figures